NutriBand Inc. 10-K

ITEM 9A. CONTROLS AND PROCEDURES Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures We conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of January 31, 2022, the end of the period covered by this annual report. The disclosure controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, who are two of our three full-time employees. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, due to our limited internal audit function, our very limited staff, and our recent acquisition of 4P Therapeutics and Pocono Coated Products, which are principally responsible for our business operations and were privately owned when we acquired them, were not effective as of January 31, 2022, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the chief executive officer/chief financial officer, as appropriate to allow timely decisions regarding disclosure. Management’s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Management assessed the effectiveness of our internal control over financial reporting as of January 31, 2022. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting as of January 31, 2022, management identified material weaknesses related to (i) our internal audit functions (ii) inadequate levels of review of the financial statements,(iii) a lack of segregation of duties within accounting functions, (iv) inadequate monitoring review controls in accounting for complex transactions. Therefore, our internal controls over financial reporting were not effective as of January 31, 2022. Management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, excessive reliance on third party consultants for accounting, financial reporting and related activities, and the lack of any separation of duties. During the past fiscal year, we have added qualified accounting personnel so the Company does not have to rely on third party consultants. The Company has established additional monitoring controls over the financial statements. We have also improved our internal controls to provide for a detailed accounting review of all revenue items, and accounts receivable and payable transactions in connection with the entry and categorization of each transaction in the preparation of the Company’s financial statements. As a result of these improvements, we are confident our financial statements as of January 31, 2022 and for the two years then ended, fairly present in all material respects our financial condition and results of operations for all that reporting period covered by this report. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate. Changes in Internal Control over Financial Reporting. During the quarterly period ended January 31, 2022, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION None. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. Not applicable. 39 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Executive Officers and Directors Set forth below is certain information with respect to our directors and executive officers: Name Age Position Gareth Sheridan 32 Chief executive officer and director Serguei Melnik 49 Chairman of the Board and President Gerald Goodman 74 Chief Financial Officer Alan Smith, Ph.D. 56 Chief operating officer and president of 4P Therapeutics Patrick Ryan 36 Chief technical officer Jeff Patrick, Pharm.D. 52 Chief scientific officer Larry Dillaha, MD 57 Chief medical officer Radu Bujoreanu 52 Director Mark Hamilton 37 Director Stefan Mancas 45 Director Irina Gram 34 Director Gareth Sheridan, our founder, has been chief executive officer and a director since our organization in 2016. In 2012, Mr. Sheridan founded Nutriband Ltd., an Irish company which we acquired in 2016. Mr. Sheridan was named Ireland’s ‘Young Entrepreneur of the Year’ in 2014 in the National Bank of Ireland Startup Awards for establishing Nutriband Ltd. Mr. Sheridan has further business awards from S. Dublin’s Best Young Entrepreneur and Nutriband Ltd as S. Dublin’s Best Startup Company. Mr. Sheridan has also worked as a Business Mentor with 100 Minds, a social enterprise founded in 2013, that brings together some of Ireland’s top college students and connects them with one cause to achieve large charitable goals in a short space of time. Mr. Sheridan is also a past Nissan Generation Next Ambassador, receiving the acknowledgement in 2015 by Nissan Ireland as one of Ireland’s future generational leaders. In 2019 Mr. Sheridan served on the Board of the St. James Hospital foundation, the charitable foundation for Ireland’s largest public hospital. Mr. Sheridan received a B.Sc. in Business and Management from Dublin Institute of Technology in 2012 where he concentrated on international economics, venture creation and entrepreneurship. Serguei Melnik, who was elected by the Board as President on October 8, 2021, serves as a member of the board of directors and is a co-founder of Nutriband Inc. Mr Melnik has previously served as our chief financial officer and a director since January 2016. Mr. Melnik has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial framework for operations of foreign companies in the U.S. Mr. Melnik advised UNR Holdings, Inc. with regard to the initiation of the trading of its stock in the over-the-counter markets in the U.S., and has provided general advice with respect to the U.S. financial markets for companies located in the U.S. and abroad. From February 2003 to May 2005, he was the Chief Operations Officer and a Board member of Asconi Corporation, Winter Park, Florida, with regard to restructuring the company and listing it on the American Stock Exchange. Mr. Melnik from June 1995 to December 1996 was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,”, Chisinau, Moldova, and prior thereto practiced law in Moldova in various positions. Mr. Melnik is fluent in Russian, Romanian, English and Spanish. Radu Bujoreanu has been a director since June 2019. Mr. Bujoreanu has been the owner and executive director of Consular Assistance, Inc., which provides assistance in obtaining visas for the Republic of Moldova and related services since December 2002, and he has been a real estate agent with Keller Williams Realty, Inc. since May 2019. Mr. Bujoreanu received his Bachelor in International Public Law from the University of Moldova. 40 Mark Hamilton, an independent director since July 2018, is an experienced director level professional who has recently joined global consulting firm, Korn Ferry as a Managing Consultant. Prior to moving into organizational consulting, Mark qualified as a Chartered Accountant in global advisory firm, BDO, where he spent 12 years advising some of Ireland’s most successful businesses. His work originated in corporate finance/corporate recovery and more recently, he spent 5 years leading BDO’s client management and sales function, as Head of Business Development. Mr. Hamilton is a Member of the Association of Chartered Accountants (ACA), since 2012. Mr. Hamilton’s accounting / consulting background and experience in corporate finance, restructuring, sales and talent assists us in his role as an independent Board member and Committee Chair. Mr. Hamilton has a very strong presence in the business community across jurisdictions, along with an accomplished track record in project management and business development. Educated at Terenure College, Mark went on to study a B.Sc. degree in Business & Management at Dublin Institute of Technology and subsequently received First Class Honours in his postgraduate degree, for which he specialised in Accountancy in 2009. In addition to his ACA qualification, Mark has also recently completed a diploma in Corporate Governance and is now a member of the Corporate Governance Institute which will assist him in his role as Independent Director. Dr. Stefaní Mancas graduated Summa cum Laude from the Military Navy College in Constanta, Romania. After attending the faculty of Cybernetics from the Academy of Economic Studies in Bucharest, she transferred to University of Central Florida, where she graduated with a dual B.Sc. in Mathematics and Aerospace Engineering, and a Ph. D. in Mathematical Sciences from the Department Mathematics. Her dissertation topic was “Dissipative solitons in the cubic-quintic complex Ginzburg-Landau equation: Bifurcations and Spatiotemporal Structure”, for which she received the UCF Outstanding Dissertation Award. Currently, Dr. Mancas is a tenured full Professor, and a researcher, in the Department of Mathematics at Embry-Riddle Aeronautical University in Daytona Beach, Florida. Her main research areas are finding analytical solutions to nonlinear evolution equations, and numerical simulations of nonlinear dissipative systems, such nonlinear Schrödinger equation with applications to quantum mechanics and biomathematics. Dr. Mancas is using techniques involving complex analysis and elliptic functions with applications to water waves, soliton theory, biological systems, and cosmology/inflation for nonlinear evolution equations, as well as applying special functions to problems involving optimization of the blockchain, where elliptic functions are used for cryptography. Dr. Mancas is the organizer of national and international conferences in mathematical physics, and as an associate editor she constantly reviews research articles for many scientific journals. Dr. Mancas holds a strong record of publications with over seventy refereed articles, and she is constantly invited to attend workshops, and speak in seminars all over the world. Irina Gram was elected as a director of the Company at the January 21, 2022 stockholders meeting. Irina is a new member of our Board, and is a Senior Financial Analyst at Thales IFEC, Melbourne, Florida. There she is responsible for financial planning, analysis and risk and opportunities reviews of multiple development and customer programs. From 2016 to 2017, she was a Project Engineering Coordinator at Thales IFEC, where she executed budgeting and forecasting activities with specialized focus on SFRD spending, interfaced with engineering team to monitor and report the performance of the financial impact of projects. From 2013 to 2016, she held various project management, accounting and reporting positions with Siemens Building Technology, Inc., Winter Park, Florida. She received a Bachelor’s Degree in Finance from the University of Central Florida, Orlando, Florida, where she graduated in May 2015, with honors, and received a Masters in Business Administration from the University of Central Florida, Orlando, Florida, in May 2019. 41 Gerald Goodman has been our chief accounting officer since July 31, 2018, and was elected our Chief Financial Officer on November 12, 2020. Mr. Goodman is a certified public accountant and, since 2014, has practiced with his own firm, Gerald Goodman CPA P.C. From January 1, 2010 until December 31, 2014, Mr. Goodman practiced with Madsen & Associates, CPA’s Inc., Murray, Utah, and was a non-equity partner and managed the firm’s SEC practice. Mr. Goodman is a director of Lifestyle Medical Network, Inc., which provides management services to healthcare providers. From 1971 to 2010, Mr. Goodman was a partner in the accounting firm of Wiener, Goodman & Company P.C. Mr. Goodman is a 1970 graduate of Pennsylvania State University where he received a B.S. Degree in Accounting. Alan Smith, Ph.D., serves as Chief Operating Officer of Nutriband and President of 4P Therapeutics, a wholly owned subsidiary of Nutriband. He joined the Company after Nutriband acquired 4P Therapeutics in 2018. Dr. Smith co-founded 4P Therapeutics in 2011 to develop drug-device and biologic-device combination products to meet the needs of patients, physicians, and payers, and was Vice President, Clinical, Regulatory, Quality and Operations at the time of the acquisition. Dr. Smith is co-inventor of the Company’s Aversa™ abuse deterrent transdermal system technology. Dr. Smith has over 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical devices for treatment and management of chronic pain, diabetes, and cardiovascular disease. Previously, he was with Altea Therapeutics, a venture capital funded company focused on novel transdermal drug and biologic delivery, most recently serving as Vice President, Product Development and Head of Clinical R&D, Regulatory Affairs, and Project Management. Prior to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company. Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery. Paddy Ryan has been chief technical officer since February 2018. Having worked in the tech industry for 8 years, Paddy brings a fresh perspective and understanding to our team. From September 2019 to present Mr. Ryan served as director of digital agency for Trigger Media. From 2013 to 2016, Mr. Ryan worked as an online security analyst with Paddy Power Betfair Plc. From 2016 to 2017, Mr. Ryan was general manager at CRS Events setting up and organising One-Zero, the largest sports conference in Ireland. Mr Ryan served as head of technology for Irish agency Trigger Movement between 2017 and 2019. Mr Ryan serves as technical advisor for sports media brand, Pundit Arena, where he has advised on their technical development since 2012. Mr Ryan also served as a digital consultant for Irish Aid Charity, Bóthar, where he worked on the development of the charity’s digital plans plans. Mr. Ryan has also consulted with Irish Local Government in County Limerick (Limerick County Council) regarding their digital activity in September 2018. Mr. Ryan has also assisted Swiss Company, SEBA Crypto AG, to develop their online presence in October 2018. Mr. Ryan is also a technical advisor for Irish dairy company, Arrabawn where he has assisted them with online strategies since 2017. Mr. Ryan has been involved in general technical consulting for startups and companies in Ireland for more than ten years. Mr. Ryan attended University College Dublin where he studied engineering and is working towards his masters in data analytics from National College of Ireland. Mr Ryan also assisted in the development and launch of the Pandemic Action Network website in early 2020. As CTO, Paddy is responsible for Nutriband’s technology strategy and plays a key role in leading new initiatives. Mr. Ryan works for us on a part-time basis. Jeff Patrick Pharm.D. currently serves as Director of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Dr. Patrick most recently serving as Chief Scientific Officer for New Haven Pharmaceuticals. Prior roles included global vice president of professional affairs at Mallinckrodt Pharmaceuticals, Inc.; and roles with ascending responsibilities at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo, Inc. Dr. Patrick is a residency-trained clinical pharmacist with approximately 20 years of pharmaceutical industry experience. He brings expertise in executive leadership, scientific and medical strategy, drug development and commercialization to the company. Prior to pursuing a career in research and development, Patrick was an ambulatory care clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy, where he earned his doctorate in pharmacy. He also completed the Wharton School of Business Pharmaceutical Executive Program. Dr. Patrick works for us on a part-time basis. Dr. Dillaha brings nearly 20 years of pharmaceutical industry experience to Nutriband. Prior to joining Nutriband, he was chief executive officer of Repros Therapeutics from February 2017 to February 2018. Prior to joining Repros, Dr. Dillaha was the chief executive officer of CavtheRx, an inception stage biotechnology company, from June 2016 to February 2017, and chief operating officer and chief medical officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. He also served as chief medical officer of Insys Therapeutics, Sciele Pharma and as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an M.D. degree from the University of Tennessee, Memphis. Dr. Dillaha works for us on a part-time basis. 42 CORPORATE GOVERNANCE AND THE BOARD OF DIRECTORS Board Leadership Structure and Risk Oversight Gareth Sheridan serves as Chief Executive Officer and Serguei Melnik is serving as our President, and following the Annual Meeting, it is expected that Serguei Melnik will commence serving as our Chairman. Our Chairman leads the Board of Directors in its discussions and has such other duties as are prescribed by the Board. As Chief Executive Officer, Mr. Sheridan is responsible for implementing the Company’s strategic and operating objectives and day-to-day decision-making related to such implementation. The Board of Directors currently has three standing committees (audit, compensation, and nominating and corporate governance) that are chaired and composed entirely of directors who are independent under Nasdaq and SEC rules. Given the role and scope of authority of these committees, and that a majority of the Board of Directors is composed of independent directors, the Board of Directors believes that its leadership structure is appropriate. We select directors as members of these committees with the expectation that they will be free of relationships that might interfere with the exercise of independent judgement. Our Board of Directors is our Company’s ultimate decision-making body, except with respect to those matters reserved to the stockholders. Our Board of Directors selects our senior management team, which is charged with the conduct of our business. Our Board of Directors acts as an advisor and counselor to senior management and oversees its performance. The position of the Chairman of our Board of Directors is served by one individual. We have determined that the leadership structure of our Board of Directors is appropriate, especially given the early stage of our development and the size of our Company. The Board of Directors oversees our exposure to risk through its interaction with management concerning matters related to financial, operational, regulatory, legal and strategic risks. Risk assessment and oversight are an integral part of our governance and management processes. Our Board of Directors encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations Board Composition Our business and affairs are managed under the direction of our Board of Directors. The number of directors is determined by our board of directors, subject to the terms of our certificate of incorporation and bylaws. Our board of directors currently consists of nine members, five of which are independent directors. Meetings Our Board of Directors acted by written consent five times during 2022. Committees of the Board of Directors The board of directors has created three committees - the audit committee, the compensation committee and the nominating and corporate governance committee. Each of the committees has a charter which meets the Nasdaq Stock Market requirements and is composed of three independent directors. Audit Committee The audit committee is comprised of Mr. Hamilton, as chairman, Mr. Bujoreanu and Ms. Irina Gram. We believe that Mark Hamilton qualifies as an “audit committee financial expert” under the rules of the Nasdaq Stock Market. The audit committee oversees, reviews, acts on and reports on various auditing and accounting matters to the board, including: the selection of our independent accountants, the scope of our annual audits, fees to be paid to the independent accountants, the performance of our independent accountants and our accounting practices, all as set forth in our audit committee charter. Compensation Committee The compensation committee is comprised of Dr. Mancas, Ms. Irina Gram and Mr. Bujoreanu. The compensation committee oversees the compensation of our chief executive officer and our other executive officers and reviews our overall compensation policies for employees generally as set forth in the audit committee charter. If so authorized by the board, the compensation committee may also serve as the granting and administrative committee under any option or other equity-based compensation plans which we may adopt. The compensation committee will not delegate its authority to fix compensation; however, as to officers who report to the chief executive officer, the compensation committee will consult with the chief executive officer, who may make recommendations to the compensation committee. Any recommendations by the chief executive officer are accompanied by an analysis of the basis for the recommendations. The committee will also discuss with the chief executive officer and other responsible officers the compensation policies for employees who are not officers. The compensation committee has the responsibilities and authority relating to the retention, compensation, oversight and funding of compensation consultants, legal counsel and other compensation advisers. The compensation committee members will consider the independence of such advisors before selecting or receiving advice from such advisors. 43 Nominating and Corporate Governance Committee The nominating and corporate governance committee, which is comprised of Mr. Hamilton, Dr. Mancas and Mr. Bujoreanu, will identify, evaluate and recommend qualified nominees to serve on our board; develop and oversee our internal corporate governance processes, and maintain a management succession plan. Independent Directors Four of our directors, Radu Bujoreanu, Mark Hamilton, Dr. Mancas and Irina Gram are independent directors based on the NASDAQ definition of independent director. Family Relationships There are no family relationships among our directors and executive officers. Compensation Committee Interlocks and Insider Participation None of our executive officers serve on the board of directors or compensation committee of a company that has an executive officer who serves on our board or compensation committee. No member of our board is an executive officer of a company in which one of our executive officers serves as a member of the board of directors or compensation committee of that company. Compliance with Section 16(a) of the Securities Exchange Act of 1934 Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors and persons who own more than 10% of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of the our common stock and other equity securities, on Form 3, 4 and 5 respectively. Mr. Sheridan and Mr. Melnik filed late Form 5s for the year ended January 31, 2020. Mr. Goodman, Dr. Smith, Mr. Ryan, Dr. Patrick, Dr. Dillaha, Mr. Bujoreanu, Mr. Hamilton, Dr. Mancas and Ms. Irina Gram have not filed their Form 3 reports. Code of Ethics Our board of directors has adopted a code of ethics applicable to our employees, directors and officers, in accordance with applicable U.S. federal securities laws and the NASDAQ regulations. Any waiver of this code may be made only by our board of directors and will be promptly disclosed as required by applicable federal securities laws and the NASDAQ corporate governance rules. The Code of Ethics is available on our website at HTTPS://Nutriband.com/ethics. Conflicts of Interest Certain conflicts of interest exist and may continue to exist between the Company and its officers and directors due to the fact that each has other business interests to which they devote their primary attention. Each officer and director may continue to do so notwithstanding the fact that management time should be devoted to the business of the Company. Certain conflicts of interest may exist between the Company and its management, and conflicts may develop in the future. The Company has not established policies or procedures for the resolution of current or potential conflicts of interest between the Company, its officers and directors or affiliated entities. There can be no assurance that management will resolve all conflicts of interest in favor of the Company, and conflicts of interest may arise that can be resolved only through the exercise by management their best judgment as may be consistent with their fiduciary duties. Management will try to resolve conflicts to the best advantage of all concerned. 44 ITEM 11. EXECUTIVE COMPENSATION Executive Compensation The table below shows the compensation for services in all capacities we paid during the years ended January 31, 2022 and 2021, to the individuals serving as our principal executive officers during the last completed fiscal year and our other two most highly paid executive officers at the end of the last completed fiscal year (whom we refer to collectively as our “named executive officers”); Name and Principal Position Year Salary $ Bonus Awards $ Stock Awards $ Option/ Awards (1) $ Incentive Plan Compensation $ Nonqualified Deferred Earnings $ All Other Compensation $ Total $ Gareth Sheridan, CEO (3) 2022 149,000 100,000 61,778 - - - 310,770 2021 60,000 150,000 - - - - 210,000 2020 42,000 15,000 - - - - - 57,000 Serguei Melnik 2022 149,000 100,000 - 61,778 - - - 310,770 President - Alan Smith 2022 148,000 - - 32,654 - - - 264,654 Chief Operating Officer - - Sean Gallagher, 2021 - - 150,000 - - - 150,000 Executive Chairman 1 2020 - - 60,000 - - - - 60,000 Jeff Patrick 2021 - - - - - - - - Chief Scientific Officer 2 2020 - - 60,000 - 252,700 - - 312,700 1 During the year ended January 31, 2021, the Company issued Mr. Gallagher 10,000 shares of common stock, valued at $150,000, as compensation. During the year ended January 31, 2020, we issued to Mr. Gallagher 8,572 shares of common stock, valued at $120,000, representing his compensation for the years ended January 31, 2019 and 2018 pursuant to his employment agreement. 2 During the year ended January 31, 2020, we issued to Strategic Pharmaceutical Consulting LLC, a company controlled by Dr. Patrick 8,572 shares of common stock, valued at $120,000, representing Dr. Patrick’s compensation for the years ended January 31, 2020 and 2019. We also granted him to an option to purchase 25,000 shares of common stock at 75% of the market price. The option expired unexercised. 3 During the year ended January 31, 2021, we issued to Gareth Sheridan, our CEO, 10,000 shares of common stock valued at $150,000, representing compensation for the year ended January 31, 2021. Non-Employee Director Compensation Table The table below shows the cash fees paid to our directors in connection with their service on our board of directors, and the stock option awards granted, during the fiscal year ended January 31, 2022. DIRECTOR COMPENSATION Name Fees Earned or Paid in Cash ($) Stock Awards ($) Option Awards ($) Non-Equity Incentive Plan Compensation ($) Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) All Other Compensation ($) Total ($) (a) (b) (c) (d) (e) (f) (g) (h) Mark Hamilton 5,000 29,340 34,340 Sean Gallagher 5,000 32,500 37,500 Radu Bujourneau 5,000 26,120 31,120 Stefani Mancas 5,000 21,222 26,222 Steven Damon 5,000 16,325 21,325 Vselovod Grigore 5,000 16,325 21,325 45 Employment Agreements with Company Officers On January 21, 2022, the Board of Directors of the Company approved Employment Agreements with Gareth Sheridan, our Chief Executive Officer, Serguei Melnik, our President and Gerald Goodman, the Company’s Chief Financial Officer. Each of the three Employment Agreements is effective February 1, 2022, for an initial term of three years, and the term is automatically extended for additional one-year periods if neither party gives notice of termination at least 90 days prior to the end of the initial term or any current additional one-year term. The Employment Agreements with Mr. Sheridan and Mr. Melnik each provide for a base salary of $250,000 per year, and the Employment Agreement with Mr. Goodman provides for a base salary of $210,000. The Employment Agreements provide for incentive payments as established by the Board of Directors, and the Employment Agreements with Mr. Sheridan and Mr. Melnik provide for a performance bonus as follows: Net Operating Profit Before Income Taxes Performance Bonus On the First $10 Million 3.5 % On the Next $40 Million 3.5 % On the Next $50 Million 3.0 % On all Amounts Over $100 Million 2.5 % Each of the Employment Agreements contains similar provisions for discharge for “cause”, including breach of the Employment Agreement or specified detrimental conduct by the employee, in which cases accrued compensation would payable as provided in the Employment Agreements. The Agreements also provide for termination by the executives for “good reason”, comprising events such as breach of the Agreement by the Company, assignment of duties inconsistent with the Executive’s position, , or in the event of a change in control of the Company. In the event of a termination by the Company without cause, or by the executive for “good reason”, the Company is required to pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts: A. the sum of (1) the executive’s annual minimum salary through the date of termination to the extent not theretofore paid, (2) any annual incentive payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred, (3) any annual performance bonus payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred,(4) any accrued and unused vacation pay and (5) any business expenses incurred by the executive that are unreimbursed as of the date of termination; B. The product of (1) the performance bonus payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; C. the amount equal to the sum of (1) three (3) times the executive’s annual minimum salary; (2) one (1) times the performance bonus payment and (3) one (1) times the incentive payment; D. In the event executive is not fully vested in any retirement benefits with the Company from pension, profit sharing or any other qualified or non-qualified retirement plan, the difference between the amounts executive would have been paid if he or she had been vested on the date his/her employment was terminated and the amounts paid or owed to the executive pursuant to such retirement plans; E. The product of (1) the incentive payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; and F. If applicable, the present value of the amount equal to the sum of five (5) years’ Performance Bonus pay with such amount being calculated based on the Performance Bonus paid to the Employee the year prior to Termination. 46 In addition, all stock options and warrants outstanding as of the date of termination and held by the executive shall vest in full and become immediately exercisable for the remainder of their full term; all restricted stock shall no longer be restricted to the extent permitted by law, and the Company will use its best efforts, at its sole cost to register such restricted stock as expeditiously as possible. The Employment Agreements of Mr. Sheridan and Mr. Melnik provide that, to the extent any payment under the Employment Agreement to the executive is subject to the excise tax imposed by section 4999 of the Internal Revenue Code, the executive is entitled to a gross-up payment from the Company to reimburse the executive for additional federal, state and local taxes imposed on executive by reason of the excise tax and the Company’s payment of the initial taxes on such amount. The Company is also required to bear the costs and expenses of any proceeding with any taxing authority in connection with the imposition of any such excise tax. Outstanding Equity Awards at Fiscal Year-End OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END Option Awards Stock Awards Name Number of Shares of Common Stock Underlying Unexercised Options (#) Exercisable Number of Securities Underlying Unexercised Options (#) Unexercisable Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) Option Exercise Price ($) Option Expiration Date Number of Shares or Units of Stock That Have Not Vested (#) Market Value of Shares or Units of Stock That Have Not Vested ($) Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) Gareth Sheridan, CEO 20,000 - - $ 5.34 January 21, 2025 - - - - Serguei Melnik, President 20,000 - - $ 5.34 January 21, 2025 - - - - Alan Smith, COO 10,000 - - $ 4.85 January 21, 2025 - - - - Gerald Goodman, CFO 10,000 - - $ 4.85 January 21, 2025 - - - - Gerald Goodman, CFO 75,000 - - $ 4.90 October 22, 2024 - - - - Jeff Patrick, CSO 10,000 - - $ 4.85 January 21, 2025 - - - - (1) The amounts reported represent the aggregate grant-date fair value of stock options awarded to certain directors in 2022, calculated in accordance with Financial Accounting Standards Board, Accounting Standards Codification Topic 718, or ASC Topic 718. The amounts presented do not correspond to the actual value that may be recognized by the named director upon vesting of the applicable awards. Bonuses Any bonuses granted in the future will relate to meeting certain performance criteria that are directly related to areas within the named executive’s responsibilities with the Company. As we continue to grow, more defined bonus programs may be established to attract and retain our employees at all levels. Other Director Compensation There are no agreements or arrangements by which any directors or nominees are to receive compensation or other payments from third parties in return for serving on the Board of Directors. Pension Benefits We currently have no plans that provide for payments or other benefits at, following, or in connection with retirement of our officers. 47 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS PRINCIPAL STOCKHOLDERS The following table provides information concerning the beneficial ownership of the Company’s common Stock by each director and nominee for director, certain executive officers, and by all directors and officers of the Company as a group as of the Record Date. In addition, the table provides information concerning the current beneficial owners, if any, known to the Company to hold more than five percent (5%) of the outstanding common Stock of the Company. The amounts and percentage of stock beneficially owned are reported based on regulations of the securities and Exchange Commission (“SEC”) governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days after December 15, 2021. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities in which he has no economic interest. The percentage of common stock beneficially owned is based on 7,821,176 shares of common stock outstanding as of April 22, 2022. Name and Address of Beneficial Owner (1) Shares of Common Stock Owned Directly Shares of Derivative Securities Owned Total Beneficial Ownership Including Option Grants (5) Percentage Gareth Sheridan(5) 1,510,000 20,000 1,530,000 19.56 % Serguei Melnik(2)(5) 707,500 20,000 727,500 9.3 % Stefani Mancas(5) 14,125 6,500 20,625 * Mark Hamilton(5) 13,750 9,000 22,750 * Radu Bujoreanu(5) 12,500 8,000 20,500, * Dr. Jeff Patrick(3)(5) 31,381 10,000 41,381 * Patrick Ryan(5) 8,750 10,000 18,750 * Allan Smith(5) 41,908 10,000 51,908 * Gerald Goodman(4)(5) 22,500 85,000 107,500 1.36 % Dr. Larry Dillaha(5) 12,500 10,000 22,500 * Irina Gram 10 10 * All officers and directors as a group (11 individuals) 2,374,924 188,500 2,563,424 32.00 % (*) Less than One (1%) Percent. (1) The address for each director and officer, unless indicated otherwise, is c/o Nutriband, Inc., 121 South Orange Ave., Suite 1500, Orlando, FL 32801. (2) Includes 25,000 shares owned by Mr. Melnik’s wife, as to which Mr. Melnik disclaims beneficial interest, and 25,000 shares owned by each of his two minor children. (3) Includes 21,072 shares owned by Strategic Pharmaceutical Consulting, with respect to which Dr. Jeff Patrick, chief scientific officer, has the power to vote and dispose of the shares. Mr. Patrick was granted a three-year option under the Company’s 2021 Employee Stock Option Plan on January 21, 2022, to purchase 10,000 shares of common stock at an exercise price of $4.85 per share. (4) Gerald Goodman holds 22,500 shares directly and was granted a three-year option under the Company’s 2021 Employee Stock Option Plan on November 20, 2021 to purchase 10,000 shares of common stock at an exercise price of $4.85 per share. Mr. Goodman also was issued on October 22, 2021 a stock purchase warrant for the purchase of 75,000 shares of common stock, exercisable at $4.90 per share. (5) On January 21, 2022, the Board of Directors approved three-year stock option grants under the Company’s 2021 Employee Stock Option Plan for an aggregate of 118,500 shares of common stock to employees and directors as compensation for services rendered in fiscal 2021, at a $4.85 per share option price, except those options issued to Gareth Sheridan and Serguei Melnik, which are exercisable at $5.34 per share. To our knowledge, all beneficial owners named in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. 48 Changes in Control We are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change in control of our company. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Issuance of Stock Options to Directors and Management During the year ended January 31, 2021, Serguei Melnik, a director and our former chief financial officer, and Dr. Alan Smith, our chief operating officer, advanced us $18,128, all of which was repaid. As of January 31, 2021, the amount due each of these officers is $-0-. On January 31, 2020, we issued 8,572 shares to each of Sean Gallagher and to Strategic Pharmaceutical Consulting LLC, which is controlled by Jeff Patrick, for services rendered by Mr. Gallaher and Dr. Patrick valued at $120,000. These issuances were made pursuant to employment agreements with Mr. Gallagher and Dr. Patrick which provide for annual compensation of $60,000 and represented compensation for the years ended December 31, 2019 and 2018. During the year ended January 31, 2021, Serguei Melnik, our chief financial officer, and Dr. Alan Smith, our chief operating officer, advanced us $18,128, all of which was repaid. As of January 31, 2021, the amounts due the officers was $-0-. On January 5, 2021, the Company issued the following numbers of shares common stock to Company officers and members of its Board of Directors. All stock issuances were valued by the Board at $15.00 per share. Gareth Sheridan, CEO and Director 10,000 Sean Gallagher, Executive Chairman and Director 10,000 Serguei Melnik, Director 10,000 Michael Myer, President of Pocono Pharma and Director 5,000 Radu Bujoreanu, Director 12,500 Steven P. Damon, Director 10,000 Michael Doron, Director* 5,000 Mark Hamilton, Director 12,500 Stefani Mancas, Director 12,500 Vsevolod Grigore, Director 5,000 Patrick Ryan, Chief Technical Officer 5,000 Gerald Goodman, Chief Financial Officer 10,000 Alan Smith, Chief Operating Officer and President of 4P Therapeutics 6,825 Vitalie Botgros, Consultant 5,000 Thomas Cooney, Director* 6,000 Jay Moore, Director* 5,000 * Former directors. 49 On January 21, 1022, the Company’s Board approved issuances as set forth below to officers and directors of stock option awards under the Corporation’s 2021 Employee Stock Option Plan which was approved by stockholders at the Annual Meeting and established the exercise price for the awards using the fair value of the common stock closing price as of January 21, 2022. The exercise price for Gareth Sheridan and Serguei Melnik was $5.34 per the terms of the Plan. Name Number of Shares Per Share Exercise Price Consideration Serguei Melnik 20,000 $ 5.34 Services rendered in fiscal 2022 Gareth Sheridan 20,000 $ 5.34 Services rendered in fiscal 2022 Gerald Goodman 10,000 $ 4.85 Services rendered in fiscal 2022 Patrick Ryan 10,000 $ 4.85 Services rendered in fiscal 2022 Larry Dillaha 10,000 $ 4.85 Services rendered in fiscal 2022 Jeff Patrick 10,000 $ 4.85 Services rendered in fiscal 2022 Mike Myer 10,000 $ 4.85 Services rendered in fiscal 2022 Sean Gallagher 10,000 $ 4.85 Services rendered in fiscal 2022 Mark Hamilton 9,000 $ 4.85 Services rendered in fiscal 2022 Radu Bujoreanu 8,000 $ 4.85 Services rendered in fiscal 2022 Stefani Mancas 6,500 $ 4.85 Services rendered in fiscal 2022 Steve Damon 5,000 $ 4.85 Services rendered in fiscal 2022 Vsevolod Grigore 5,000 $ 4.85 Services rendered in fiscal 2022 Tyler Overk 10,000 $ 4.85 Services rendered in fiscal 2022 Diana Mather 10,000 $ 4.85 Services rendered in fiscal 2022 Alan Smith 10,000 $ 4.85 Services rendered in fiscal 2022 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES The following table sets forth the fees billed by our independent accountants, Sadler, Gibb & Associates, LLC, for each of our last two years for the categories of services indicated. Year Ended January 31 2022 2021 Audit fees $ 69,250 $ 63,500 Audit – related fees 12,200 - Tax fees - - All other fees $ - $ 65,637 Audit fees consist of fees related to professional services rendered in connection with the audit of our annual financial statements and review of our interim financial statements. All other fees relate to professional services rendered in connection with our registration statements and acquisition audits. Our policy is to pre-approve all audit and permissible non-audit services performed by the independent accountants. These services may include audit services, audit-related services, tax services and other services. Under our audit committee’s policy, pre-approval is generally provided for particular services or categories of services, including planned services, project based services and routine consultations. In addition, the audit committee may also pre-approve particular services on a case-by-case basis. Our board approved all services that our independent accountants provided to us in the past two fiscal years. 50 PART IV ITEM 15. Exhibits. Exhibit Number Description 3.1A Articles of Incorporation. (Filed as Exhibit 3.1A to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.) 3.1B Amendment to Articles of Incorporation, filed May 12, 2016. 2(Filed as Exhibit 3.1B to the e Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.) 3.1 Certificate of Amendment filed January 22, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020). 3.2 By-laws (1) 3.2B Amended and Restated By-Laws adopted January 21, 2022. (12) 4.3 Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC (6) 4.4 Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 (6) 4.10 Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC (6) 4.12 Form of Underwriter’s Warrant (9) . 4.13 Form of Warrant Agent Agreement (9) . 4.14 2021 Employee Stock Option Plan. (11) 4.15 Form of Stock Option Grant Notice . (11) 10.1 Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee (1) 10.4 Acquisition agreement dated April 5, 2018 between the Company and 4P Therepeutics LLC. (3) 10.5 Form of agreement with independent directors. (4) 10.6 Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc. (4) 10.15 Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company. (5) 10.16 Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company. (5) 10.17 Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company. (5) 10.18 Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company. (5) 10.19 Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC. (7) 10.20 Security Agreement, between the Company and Pocono Coated Products, LLC. (7) 10.21 Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC. (7) 10.22 License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd. (8) 10.23 Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd. (8) 10.24 Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd. (8) 10.25 Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC (8a) 10.26 Services Agreement October 4, 2021, between Active Intelligence, LLC and Diomics Corporation. (10) 10.27 Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan. (12) 10.28 Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik. (12) 10.29 Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman. (12) 31.1 Certification of Principal Executive Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002). 99.1 Audit Committee Charter (4) 99.2 Compensation Committee Charter (4) 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). (1) Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference. (2) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on May 23, 2017 and incorporated herein by reference. 51 (3) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference. (4) Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference. (5) Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference. (6) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019. (7) Filed as an exhibit to the Company’s report on form 8-K, which was filed with the Commission on September 4, 2020. (8) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021. (8a) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021. (9) Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021. (10) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021. (11) Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021. (12) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022. (10) To be filed by Amendment. ITEM 16. FORM 10-K SUMMARY Not applicable. 52 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: April 28, 2022 NUTRIBAND INC. By: /s/ Gareth Sheridan Gareth Sheridan Chief Executive Officer By: /s/ Gerald Goodman Gerald Goodman Chief Financial Officer (Principal Financial and Accounting Officer) Signature Title Date /s/ Gareth Sheridan Chief Executive Officer and Director April 28, 2022 Gareth Sheridan /s/ Serguei Melnik Director April 28, 2022 Serguei Melnik /s/ Radu Bujoreanu Director April 28, 2022 Radu Bujoreanu /s/ Mark Hamilton Director April 28, 2022 Mark Hamilton /s/ Stefan Mancas Director April 28, 2022 Stefan Mancas /s/ Irina Gram Director April 28, 2022 Irina Gram 53